<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653913</url>
  </required_header>
  <id_info>
    <org_study_id>P03962</org_study_id>
    <nct_id>NCT00653913</nct_id>
  </id_info>
  <brief_title>Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)</brief_title>
  <official_title>Evaluation of Potential for Pharmacokinetic Drug Interaction Between SCH 58235 and Pitavastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the pharmacokinetic interaction and safety of
      coadministration of SCH 58235 (ezetimibe) and pitavastatin in healthy Japanese adult male
      subjects or adult male subjects having no obvious disease other than high cholesterol levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin after administration of each drug alone and in combination, using Cmax and AUC(0-24h).</measure>
    <time_frame>Day 7 of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin administration of each drug alone and in coadministration, using Tmax, plasma concentration 24 h after last dose, and AUC(I).</measure>
    <time_frame>Day 7 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, laboratory tests results, and vital signs.</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 58235</intervention_name>
    <description>SCH 58235 10 mg (once daily)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <other_name>Ezetimibe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin</intervention_name>
    <description>Pitavastatin 2 mg (once daily)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male subjects meeting all the criteria below or adult male subjects
             having no obvious disease other than high cholesterol levels.

          -  Aged 20 years or over and 65 years or below when the informed consent is obtained.

          -  Weighing 50 kg or over and 80 kg or below on the day of the screening tests, with BMI
             [Body Mass Index: body weight (kg)/height (m)2] ranging from 16.5 to 27.5.

        Exclusion Criteria:

        Patients meeting any one of the following conditions are excluded from the study.

          -  Subjects with the triglyceride value at screening test exceeding 500 mg/dL.

          -  Subjects with past history of drug allergy (shock, anaphylactic symptom, and
             angioedema).

          -  Subjects with past history of alcohol or drug dependence.

          -  Subjects with past history of mental disorder.

          -  Subjects positive in the test for HBs antigen, HCV antibody, or HIV antibody or in the
             serological test for syphilis.

          -  Subjects who used any drug within 2 weeks of investigational product administration in
             Period 1.

          -  Subjects who have drawn more than 400 mL of blood within 12 weeks before
             administration day in Period 1.

          -  Subjects who participated in other study within 16 weeks of investigational product
             administration in Period 1 and was administered a investigational product.

          -  Subjects who cannot take contraceptive measures during the study period (from
             providing informed consent to completion of Period 3 examination)

          -  Subjects who the investigator judges are inappropriate to participate in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

